the staff of the Ridgewood blog
West Orange NJ, RWJBarnabas Health is proud to have been a participant in one of the Gilead trials to assess antiviral Remdesivir as a treatment for patients with severe COVID-19. Gilead recently announced promising top line results that show similar efficacy with 5- and 10- day dosing durations of the drug.
With just a handful of participating hospitals in New Jersey, three RWJBarnabas Health facilities collectively recruited and enrolled nearly 140 patients in the trial over the past month. Participating facilities: Robert Wood Johnson University Hospital Somerset, Robert Wood Johnson University Hospital New Brunswick, and Newark Beth Israel Medical Center.
“COVID-19 has ravaged our state in many ways. As frontline workers we have been professionally involved with this pandemic from day one. As New Jersey residents, we have seen the economic impact that social distancing and quarantines have had on our businesses, and we’ve all felt the pain of being physically isolated from our friends and loved ones. We’re honored to be part of this promising treatment,” said Anthony Cava, President and CEO, Robert Wood Johnson University Hospital Somerset.
Remdesivir, a drug developed by research-based biopharmaceutical company Gilead Sciences, Inc., has shown antiviral activity against multiple emerging viral pathogens, including Ebola, Marburg, MERS, SARS and now COVID-19. The clinical trials assess safety and efficacy of Remdesivir as a treatment for patients with COVID-19.
“We are excited to play a vital role in determining the efficacy of this promising new therapy, said Darrell K. Terry, Sr., MHA, MPH, FACHE, President and Chief Executive Officer, Newark Beth Israel Medical Center.
RWJBarnabas Health continued its role in the international study until it reached completion, having recruited patients for the trial and through analysis and reporting of the results in conjunction with Gilead. RWJBarnabas is no long enrolling patients in the trial because Gilead announced today that the critical number of subjects has been met.
“While we only recruited patients for 7 weeks, because of the virus’ impact in New Jersey we were able to enroll 139 patients,” said Ronald G Nahass, MD, MHCM, an infectious disease specialist at RWJUH in New Brunswick and RWJUH Somerset, where he is also the hospital’s epidemiologist, who led the RWJBarnabas Health teams as principal investigator for the trial. “Thankfully, the number of infected individuals in our area is flattening”..
“Making sure our communities remain healthy is our chief goal,” said John J. Gantner, President and Chief Executive Officer of Robert Wood Johnson University Hospital New Brunswick. “We’re grateful for the ability to have brought our research acumen to this trial and work alongside teams across the country to move toward a treatment for this terrible virus, and benefit not only the people of New Jersey, but those around the globe suffering from COVID-19.”